Viking Therapeutics (LTS:0VQA) Research & Development: $453.72 Mil (TTM As of Mar. 2026)


LTS:0VQA Viking Therapeutics Inc LTS:0VQA
36 GF Score
Price $37.72
! 3 Warning Signs
View Full Analysis

What is Viking Therapeutics Research & Development?

Viking Therapeutics LTS:0VQA -6.86% 36 Research & Development is $453.72 Mil as of Mar. 2026. GuruFocus rates LTS:0VQA with a GF Score™ of 36/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Viking Therapeutics's Research & Development for the three months ended in Mar. 2026 was $150.15 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $453.72 Mil.

Viking Therapeutics  (LTS:0VQA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Viking Therapeutics Research & Development Related Terms

Viking Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Viking Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viking Therapeutics Research & Development Chart

Viking Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 44.98 54.23 63.81 101.64 344.96

Viking Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.39 60.15 89.95 153.46 150.15
LTS:0VQA
36GF Score
Viking Therapeutics Inc LTS:0VQA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viking Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $453.72 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $453.72 Mil mean?
Viking Therapeutics (LTS:0VQA) has a Research & Development of $453.72 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Viking Therapeutics and its competitors.
Is Viking Therapeutics' Research & Development too high?
Viking Therapeutics' current Research & Development is $453.72 Mil. Overall, Viking Therapeutics has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Viking Therapeutics' Research & Development compare to EWTX and ACAD?
Viking Therapeutics' Research & Development of $453.72 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Viking Therapeutics and its competitors. Viking Therapeutics's current Research & Development is $453.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viking Therapeutics stock overvalued right now?
Viking Therapeutics (LTS:0VQA) has a current Research & Development of $453.72 Mil. The current Research & Development is $453.72 Mil. Viking Therapeutics' overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Viking Therapeutics (LTS:0VQA), the current Research & Development is $453.72 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viking Therapeutics Business Description

Address 9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, USA, 92121
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
36GF Score

Get the complete analysis for LTS:0VQA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$37.72
Price